🔗 Share this article

While the US continues making unprecedented changes to its vaccination guidelines, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by casting doubt on coronavirus shots throughout the global health crisis and has focused upon potential fatalities after Covid vaccination in her brief position at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Program

Health officials planned to reveal major revisions to the pediatric vaccine schedule earlier this month, aligning the US with the Danish immunization schedule, sources say – a significant shift that would put the US out of step with a large portion of the global community with no evidence for public health gain. The announcement has been postponed until the new year.

In place of Vinay Prasad, Dr. Høeg is set to speak at the gathering. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to lead the office this calendar year.

Consolidating Power at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it signals a renewed priority upon reevaluating previously authorized immunizations at the FDA.

The new acting director has repeatedly called for halting certain childhood immunization guidelines in the US to become more similar to Denmark, a society with nationalized medicine and a number of inhabitants approximately the population of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccines – typically the responsibility of Prasad, chief of the FDA’s CBER – instead of medication approval.

Questions Over Expertise

Dr. Høeg has no obvious background in drug development, regulation or administrative roles, which has been customary for former directors of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“She appears not to have the requisite experience” for leading the drug-regulation department, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in managing a large organization. She lacks background in industry regulation.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, commented a former acting FDA commissioner. “Frankly, she lacks the kind of background that former directors who headed the center have had.”

The drug center has an vast range of responsibilities at the FDA, she pointed out.

“Everybody just focuses on the new drug program, but the off-patent medication office clears numerous generic medications. There is also a biologic copycat branch, OTC medication office and so forth, and every single one need to be supervised,” Woodcock explained. “The area you overlook, that is the part that I always told people is going to cause problems.”

There is also, a significant administrative component to the job, which supervises in excess of 5,000 personnel. “It’s a huge administrative position, if you perform it correctly,” she said.

Agency Reaction and Contentious Initiatives

Regarding questions about Dr. Høeg's fitness for the role and whether this assignment represents more teamwork among agency officials on immunizations, a press secretary stated that the “inquiries are based on flawed assumptions”.

“Her experience is consistent with the functions of her job,” the representative stated, citing the time Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg takes over the commissioner’s new expedited review system, a disputed expedited therapy clearance system that reportedly concerned her former heads. “How are these therapies being picked for this voucher program? Who makes the decisions?” Howard said. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he stated, “the agency looks to be trending towards less stringent regulations of most medications, with the exception of vaccines.”

Public History on Vaccines

Concerning immunizations, Høeg has a more documented, if problematic, history, Howard said. She published a research paper using unverified volunteer-provided data to assess the frequency of heart inflammation after COVID-19 vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “policy goals” for the current government featured altering guidelines for new vaccines and ending “unnecessary” vaccines, she said after the election on a podcast. At the FDA, Dr. Høeg has according to sources proposed preventing young men from obtaining Covid vaccinations.

“She is an complete ideologue who starts off with her preconceived notions and works backwards to accommodate the evidence in a very deceptive, untruthful manner,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Høeg aligned with other dissenters, {like|